Hodgkin lymphoma is relatively rare. It accounts for roughly 0.4% of all new cancer diagnoses, with about 82,500 new cases reported worldwide in 2022. In the United States, approximately 8,000 to 9,000 people are diagnosed each year. Despite its rarity, it’s one of the most treatable cancers, with five-year survival rates above 80% even at advanced stages.
Who Gets Hodgkin Lymphoma
Unlike most cancers, Hodgkin lymphoma follows a distinctive two-peak pattern across age groups. The first and larger peak hits between ages 15 and 35, making it one of the more common cancers in young adults. The second peak occurs at age 55 and older. This bimodal pattern is unusual in oncology and means the disease affects people at very different life stages.
Among children, Hodgkin lymphoma accounts for about 6.5% of all childhood cancers. The incidence climbs sharply with age: adolescents aged 15 to 19 are diagnosed at roughly 30 times the rate of children under 5. Kids aged 5 to 9 have about a tenfold lower rate than older teens, and those aged 10 to 14 fall roughly threefold below the adolescent peak. Men are diagnosed slightly more often than women overall, though the gap narrows in the young adult age group.
How It Compares Globally
Hodgkin lymphoma rates vary by geography. Europe has the highest incidence rates in the world, while Africa, despite having lower incidence, reports the highest mortality rates, likely reflecting differences in access to treatment and early diagnosis. The United States and other high-income countries fall somewhere in between for incidence but benefit from high survival rates due to effective therapies.
Subtypes and Their Frequency
Not all Hodgkin lymphoma is the same. About 95% of cases fall under “classical” Hodgkin lymphoma, which breaks down into four subtypes with very different frequencies. In a large analysis of over 13,000 patients, nodular sclerosis was by far the most common, representing 79% of cases. This subtype is especially prevalent in young adults. Mixed cellularity accounted for 16%, and is more common in older patients and in developing countries. The remaining two subtypes, lymphocyte-rich (4%) and lymphocyte-depleted (1%), are uncommon. The rare fifth form, nodular lymphocyte-predominant Hodgkin lymphoma, makes up the remaining roughly 5% of all diagnoses and behaves differently enough that it’s often treated with a separate approach.
Risk Factors That Affect Your Odds
For most people, the lifetime risk of developing Hodgkin lymphoma is low. But certain factors shift the odds. Having a first-degree relative (parent, sibling, or child) with the disease raises your risk about threefold compared to the general population. Siblings face a higher relative risk than parents or offspring, suggesting shared early-life environmental exposures may play a role alongside genetics.
Infection with Epstein-Barr virus, the virus that causes mononucleosis, is linked to a portion of cases, particularly the mixed cellularity subtype and cases diagnosed in older adults. A weakened immune system, whether from an autoimmune condition or other causes, also increases risk. Still, the absolute numbers remain small: even a threefold increase on a rare cancer means the vast majority of people with a family history will never develop it.
Survival by Stage at Diagnosis
One of the most reassuring aspects of Hodgkin lymphoma is how treatable it is across all stages. SEER data from 2016 to 2022 shows five-year relative survival rates that would be the envy of most cancer types:
- Stage I (confined to a single region): 92.7%
- Stage II (involving multiple regions on the same side of the diaphragm): 95.4%
- Stage III (spread to both sides of the diaphragm): 87.7%
- Stage IV (widespread involvement): 82.8%
Stage II actually has a slightly higher survival rate than Stage I, which may seem counterintuitive. This likely reflects the fact that Stage II disease in young adults, who tend to respond exceptionally well to treatment, makes up a large share of those cases. Even Stage IV disease carries better than an 80% five-year survival rate, a figure that has improved steadily over the past several decades as treatment options have expanded.
The combination of its rarity, its tendency to strike younger people, and its high cure rate makes Hodgkin lymphoma unusual among cancers. For the roughly 8,000 to 9,000 Americans diagnosed each year, the prognosis is substantially better than for most other cancers caught at a similar stage.